1734 related articles for article (PubMed ID: 22805174)
21. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
22. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
[TBL] [Abstract][Full Text] [Related]
23. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
Haubrich R; Berger D; Chiliade P; Colson A; Conant M; Gallant J; Wilkin T; Nadler J; Pierone G; Saag M; van Baelen B; Lefebvre E;
AIDS; 2007 Mar; 21(6):F11-8. PubMed ID: 17413685
[TBL] [Abstract][Full Text] [Related]
24. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
[TBL] [Abstract][Full Text] [Related]
27. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
Toulson AR; Harrigan R; Heath K; Yip B; Brumme ZL; Harris M; Hogg RS; Montaner JS
J Infect Dis; 2005 Nov; 192(10):1787-93. PubMed ID: 16235178
[TBL] [Abstract][Full Text] [Related]
28. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.
Torti C; Prosperi M; Motta D; Digiambenedetto S; Maggiolo F; Paraninfo G; Ripamonti D; Cologni G; Fabbiani M; Caputo SL; Sighinolfi L; Ladisa N; El-Hamad I; Quiros-Roldan E; Frank I
Clin Microbiol Infect; 2012 May; 18(5):449-58. PubMed ID: 21919996
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
[TBL] [Abstract][Full Text] [Related]
30. Impaired CD4 T-cell count response to combined antiretroviral therapy in antiretroviral-naive HIV-infected patients presenting with tuberculosis as AIDS-defining condition.
Cingolani A; Cozzi Lepri A; Castagna A; Goletti D; De Luca A; Scarpellini P; Fanti I; Antinori A; d'Arminio Monforte A; Girardi E
Clin Infect Dis; 2012 Mar; 54(6):853-61. PubMed ID: 22157323
[TBL] [Abstract][Full Text] [Related]
31. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
32. Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?
Girard PM; Nelson M; Mohammed P; Hill A; van Delft Y; Moecklinghoff C
AIDS; 2013 Nov; 27(17):2759-63. PubMed ID: 23842127
[TBL] [Abstract][Full Text] [Related]
33. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
34. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
35. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy.
Gianotti N; Soria A; Galli L; Castagna A; Cernuschi M; Hasson H; Lazzarin A
J Med Virol; 2004 Feb; 72(2):181-6. PubMed ID: 14695657
[TBL] [Abstract][Full Text] [Related]
36. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
37. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
[TBL] [Abstract][Full Text] [Related]
38. Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy.
Li T; Wu N; Dai Y; Qiu Z; Han Y; Xie J; Zhu T; Li Y
Clin Infect Dis; 2011 Nov; 53(9):944-51. PubMed ID: 21960716
[TBL] [Abstract][Full Text] [Related]
39. Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Launay O; Duval X; Dalban C; Descamps D; Peytavin G; Certain A; Mouajjah S; Ralaimazava P; Verdon R; Costagliola D; Clavel F;
Antivir Ther; 2006; 11(7):889-99. PubMed ID: 17302251
[TBL] [Abstract][Full Text] [Related]
40. HIV type 1 DNA development during long-term supervised therapy interruption.
Eriksson LE; Falk KI; Bratt GA; Leandersson AC; Wahren B; Leitner T
AIDS Res Hum Retroviruses; 2003 Apr; 19(4):259-65. PubMed ID: 12804001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
